Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Concurrent Chemotherapy and ZD1839 (IRESSA) With Hyperfractionated Radiation Therapy, Followed by Maintenance ZD1839 (IRESSA) for Patients With Locally Advanced Squamous Cell Head and Neck Cancer

NCT00352105 is registered in ClinicalTrials.gov with David Adelstein as lead sponsor.

NCT NCT00352105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00352105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Concurrent Chemotherapy and ZD1839 (IRESSA) With Hyperfractionated Radiation Therapy, Followed by Maintenance ZD1839 (IRESSA) for Patients With Locally Advanced Squamous Cell Head and Neck Cancer
Lead sponsor
David Adelstein
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2006
Completion date
May 31, 2010
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer